Vertex Pharmaceuticals Incorporated
VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of aā¦ read more
Healthcare
Biotechnology
34 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$392.79
Price+0.64%
$2.49
1Y
Price
Market Cap
$100.708b
Large
Price/Earnings 3y Avg5y Avg
28x
Premium
Premium
Financials Overview
Key metrics over the past few years+48.0%
EBITDA Margin+34.8%
Net Profit Margin+31.3%
Free Cash Flow MarginRevenue
$11.419b
+3.6%
1y CAGR+8.6%
3y CAGR+10.9%
5y CAGREarnings
$3.638b
+779.2%
1y CAGR+224.4%
3y CAGR+178.8%
5y CAGREPS
$13.99
+772.6%
1y CAGR+222.0%
3y CAGR+177.1%
5y CAGRBook Value
$17.175b
$24.037b
Assets$6.861b
Liabilities$1.527b
DebtDebt to Assets
6.4%
0.3x
Debt to EBITDAFree Cash Flow
$3.500b
+542.8%
1y CAGR+134.1%
3y CAGR+116.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company